We are Zogenix.
We are a premier specialty pharmaceutical company providing innovative therapeutics to patients. Our focus is on improving patient outcomes by developing and responsibly commercializing differentiated products through unique drug delivery systems for CNS disorders and pain.
We broadly leverage our drug delivery technologies with partners for the benefit of physicians and patients in other therapeutic areas. We are building an organization that makes a difference in the lives of patients and our employees through the principles of ethical decision making, open communication and collaboration.
Zogenix represents the intersection of where medicine meets technology. We were established in 2006 by an experienced pharmaceutical commercial leader who launched multiple new therapies including sumatriptan injection in 1993 and by an experienced pharmaceutical scientist who has developed multiple drug delivery technologies including DosePro.
Our first commercial product, SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Taking an existing formulation, sumatriptan injection, and combining it with the ease of DosePro technology, we have been able to re-introduce a much needed treatment option for migraine sufferers.
Our lead product candidate, Zohydro ER™ (hydrocodone bitartrate), Zohydro ER is an oral, single-entity (without acetaminophen) novel extended-release formulation of various strengths of hydrocodone intended for administration every 12 hours for around the clock management of moderate to severe chronic pain.
Our second investigational product candidate, Relday™, is a proprietary, once-monthly subcutaneous formulation of risperidone for the treatment of schizophrenia.
Our validated, proprietary DosePro needle-free technology platform has a broad range of applications, and can be an ideal solution for self administration of subcutaneous pharmaceuticals and biologics.
Innovation is key to our success. In 2010, we were honored to receive the Most Innovative Product Award in the Life Sciences category from CONNECT for SUMAVEL DosePro. We take pride in our approach to product development, commercialization strategy and delivering results.
But mostly, we take pride in our employees and how we conduct our business on a daily basis.
We are Zogenix.